{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:14:39Z","timestamp":1793747679830,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Rationale &amp; objective<\/jats:title>\n                <jats:p>Glomerulonephritis (GN) is a leading cause of chronic kidney disease (CKD). Major adverse cardiovascular events (MACE) are prolific in CKD. The risk of MACE in GN cohorts is multifactorial. We investigated the prognostic significance of routine cardiac biomarkers, Troponin I and N-terminal pro-BNP (NT-proBNP) in predicting MACE within 5 years of GN diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Study Design<\/jats:title>\n                <jats:p>Retrospective cohort study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Setting &amp; participants<\/jats:title>\n                <jats:p>Data were obtained from TriNetX, a global federated health research network of electronic health records (EHR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Exposure or predictor<\/jats:title>\n                <jats:p>Biomarker thresholds: Troponin I: 18 ng\/L, NT-proBNP: 400 pg\/mL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Outcomes<\/jats:title>\n                <jats:p>Primary outcome: Incidence of major adverse cardiovascular events (MACE). Secondary outcome: was the risk for each individual component of the composite outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Analytical Approach<\/jats:title>\n                <jats:p>1:1 propensity score matching using logistic regression. Cox proportional hazard models were used to assess the association of cardiac biomarkers with the primary and secondary outcomes, reported as Hazard Ratio (HR) and 95% confidence intervals (CI). Survival analysis was performed which estimates the probability of an outcome over a 5-year follow-up from the index event.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Following PSM, 34,974 and 18,218 patients were analysed in the Troponin I and NTproBNP cohorts, respectively. In the Troponin I all cause GN cohort, 3,222 (9%) developed composite MACE outcome HR 1.79; (95% CI, 1.70, 1.88, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). In the NTproBNP GN cohort, 1,686 (9%) developed composite MACE outcome HR 1.99; (95% CI, 1.86, 2.14, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Limitations<\/jats:title>\n                <jats:p>The data are derived from EHR for administrative purposes; therefore, there is the potential for data errors or missing data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In GN, routinely available cardiac biomarkers can predict incident MACE. The results suggest the clinical need for cardiovascular and mortality risk profiling in glomerular disease using a combination of clinical and laboratory variables.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-024-03667-y","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T08:01:54Z","timestamp":1721635314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Routine cardiac biomarkers for the prediction of incident major adverse cardiac events in patients with glomerulonephritis: a real-world analysis using a global federated database"],"prefix":"10.1186","volume":"25","author":[{"given":"Elin Mitford","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J. R.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Oni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudh","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"issue":"10225","key":"3667_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"Global","year":"2020","unstructured":"Global. Regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333.","journal-title":"Lancet"},{"issue":"11","key":"3667_CR2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular Disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157\u201372.","journal-title":"Circulation"},{"issue":"2","key":"3667_CR3","doi-asserted-by":"publisher","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","volume":"290","author":"ND Vaziri","year":"2006","unstructured":"Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Ren Physiol. 2006;290(2):F262\u2013272.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"17","key":"3667_CR4","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108(17):2154\u201369.","journal-title":"Circulation"},{"issue":"6","key":"3667_CR5","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","volume":"67","author":"AS Levey","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67(6):2089\u2013100.","journal-title":"Kidney Int"},{"key":"3667_CR6","unstructured":"Registry UR, UK Renal Registry. (2022) UK renal registry 24th annual report \u2013 data to 31\/12\/2020. Vol 20232022."},{"issue":"6","key":"3667_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1053\/j.ajkd.2022.04.005","volume":"80","author":"M Canney","year":"2022","unstructured":"Canney M, Gunning HM, Zheng Y, et al. The risk of cardiovascular events in individuals with primary glomerular diseases. Am J Kidney Dis. 2022;80(6):740\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"3667_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","volume":"2","author":"LW Miller","year":"2002","unstructured":"Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transpl. 2002;2(9):807\u201318.","journal-title":"Am J Transpl"},{"issue":"12","key":"3667_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","volume":"14","author":"CJ Ferro","year":"2018","unstructured":"Ferro CJ, Mark PB, Kanbay M, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14(12):727\u201349.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"3667_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/01.CIR.0000133312.96477.48","volume":"110","author":"K Klausen","year":"2004","unstructured":"Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32\u20135.","journal-title":"Circulation"},{"key":"3667_CR11","volume-title":"ICD-10: international statistical classification of diseases and related health problems : tenth revision","author":"O World Health","year":"2004","unstructured":"World Health O. ICD-10: international statistical classification of diseases and related health problems : tenth revision. 2nd ed. Geneva: World Health Organization; 2004.","edition":"2"},{"key":"3667_CR12","unstructured":"Medicine TIFoCCaL. High-Sensitivity* Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer. IFCC Committee on Clinical Applications of Cardiac Bio-Markers (C-CB) v052022. Available online https:\/\/ifcc.web.insd.dk\/media\/479435\/high-sensitivity-cardiac-troponin-i-and-t-assay-analytical-characteristics-designated-by-manufacturer-v052022.pdf."},{"key":"3667_CR13","unstructured":"Guo S, Fraser MW. Propensity score analysis: statistical methods and applications; 2014."},{"issue":"21","key":"3667_CR14","doi-asserted-by":"publisher","first-page":"e012336","DOI":"10.1161\/JAHA.119.012336","volume":"8","author":"N Bansal","year":"2019","unstructured":"Bansal N, Zelnick L, Go A, et al. Cardiac biomarkers and risk of Incident Heart failure in chronic kidney disease: the CRIC (chronic renal insufficiency cohort) study. J Am Heart Assoc. 2019;8(21):e012336.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"3667_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000495946","volume":"141","author":"J Savoj","year":"2019","unstructured":"Savoj J, Becerra B, Kim JK, et al. Utility of cardiac biomarkers in the setting of kidney disease. Nephron. 2019;141(4):227\u201335.","journal-title":"Nephron"},{"issue":"18","key":"3667_CR16","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1093\/eurheartj\/ehs163","volume":"33","author":"L Scheven","year":"2012","unstructured":"Scheven L, de Jong PE, Hillege HL, et al. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J. 2012;33(18):2272\u201381.","journal-title":"Eur Heart J"},{"key":"3667_CR17","doi-asserted-by":"publisher","first-page":"2314128","DOI":"10.1155\/2020\/2314128","volume":"2020","author":"M Provenzano","year":"2020","unstructured":"Provenzano M, Andreucci M, De Nicola L, et al. The role of prognostic and predictive biomarkers for assessing Cardiovascular risk in chronic kidney Disease patients. Biomed Res Int. 2020;2020:2314128.","journal-title":"Biomed Res Int"},{"issue":"8","key":"3667_CR18","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1681\/ASN.2005121288","volume":"17","author":"CDA Stehouwer","year":"2006","unstructured":"Stehouwer CDA, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol. 2006;17(8):2106\u201311.","journal-title":"J Am Soc Nephrol"},{"issue":"4 Suppl 1","key":"3667_CR19","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1053\/ajkd.2001.27383","volume":"38","author":"W Weinstock Brown","year":"2001","unstructured":"Weinstock Brown W, Keane WF. Proteinuria and cardiovascular disease. Am J Kidney Dis. 2001;38(4 Suppl 1):S8\u201313.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3667_CR20","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.kint.2015.12.041","volume":"89","author":"T Lee","year":"2016","unstructured":"Lee T, Derebail VK, Kshirsagar AV, et al. Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int. 2016;89(5):1111\u20138.","journal-title":"Kidney Int"},{"issue":"3","key":"3667_CR21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ki.1993.292","volume":"44","author":"JD Ordo\u00f1ez","year":"1993","unstructured":"Ordo\u00f1ez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993;44(3):638\u201342.","journal-title":"Kidney Int"},{"issue":"9","key":"3667_CR22","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1681\/ASN.2020111583","volume":"32","author":"AS Go","year":"2021","unstructured":"Go AS, Tan TC, Chertow GM, et al. Primary nephrotic syndrome and risks of ESKD, Cardiovascular events, and death: the kaiser permanente nephrotic syndrome study. J Am Soc Nephrol. 2021;32(9):2303\u201314.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3667_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5414\/CNP63173","volume":"63","author":"B Mackinnon","year":"2005","unstructured":"Mackinnon B, Deighan CJ, Norrie J, Boulton-Jones JM, Sattar N, Fox JG. The link between circulating markers of endothelial function and proteinuria in patients with primary glomerulonephritis. Clin Nephrol. 2005;63(3):173\u201380.","journal-title":"Clin Nephrol"},{"issue":"4","key":"3667_CR24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/path.3964","volume":"226","author":"AH Salmon","year":"2012","unstructured":"Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. J Pathol. 2012;226(4):562\u201374.","journal-title":"J Pathol"},{"key":"3667_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cca.2015.05.013","volume":"447","author":"FT Salmito","year":"2015","unstructured":"Salmito FT, de Oliveira Neves FM, Meneses GC, de Almeida Leit\u00e3o R, Martins AM, Lib\u00f3rio AB. Glycocalyx injury in adults with nephrotic syndrome: association with endothelial function. Clin Chim Acta. 2015;447:55\u20138.","journal-title":"Clin Chim Acta"},{"issue":"4","key":"3667_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1440-1797.2012.01575.x","volume":"17","author":"Q Zhang","year":"2012","unstructured":"Zhang Q, Zeng C, Fu Y, Cheng Z, Zhang J, Liu Z. Biomarkers of endothelial dysfunction in patients with primary focal segmental glomerulosclerosis. Nephrol (Carlton). 2012;17(4):338\u201345.","journal-title":"Nephrol (Carlton)"},{"issue":"8311","key":"3667_CR27","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","volume":"2","author":"JF Moorhead","year":"1982","unstructured":"Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2(8311):1309\u201311.","journal-title":"Lancet"},{"issue":"1","key":"3667_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrneph.2017.155","volume":"14","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14(1):57\u201370.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"3667_CR29","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.kint.2022.06.023","volume":"102","author":"W Zeng","year":"2022","unstructured":"Zeng W, Beyene HB, Kuokkanen M, et al. Lipidomic profiling in the strong heart study identified American indians at risk of chronic kidney disease. Kidney Int. 2022;102(5):1154\u201366.","journal-title":"Kidney Int"},{"issue":"5","key":"3667_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"FP Schena","year":"2018","unstructured":"Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38(5):435\u201342.","journal-title":"Semin Nephrol"},{"issue":"1","key":"3667_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12882-021-02353-7","volume":"22","author":"S Jarrick","year":"2021","unstructured":"Jarrick S, Lundberg S, Sundstr\u00f6m J, Symreng A, Warnqvist A, Ludvigsson JF. Immunoglobulin a nephropathy and ischemic heart disease: a nationwide population-based cohort study. BMC Nephrol. 2021;22(1):165.","journal-title":"BMC Nephrol"},{"issue":"1","key":"3667_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12882-022-02909-1","volume":"23","author":"B S\u00e1gi","year":"2022","unstructured":"S\u00e1gi B, K\u00e9s\u0151i I, Vas T, Csiky B, Nagy J, Kov\u00e1cs TJ. Left ventricular myocardial mass index associated with cardiovascular and renal prognosis in IgA nephropathy. BMC Nephrol. 2022;23(1):285.","journal-title":"BMC Nephrol"},{"issue":"12","key":"3667_CR33","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.2215\/CJN.00520121","volume":"16","author":"KA Birdwell","year":"2021","unstructured":"Birdwell KA, Park M. Post-transplant cardiovascular disease. Clin J Am Soc Nephrol. 2021;16(12):1878\u201389.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9800","key":"3667_CR34","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S0140-6736(11)61334-2","volume":"378","author":"AG Jardine","year":"2011","unstructured":"Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011;378(9800):1419\u201327.","journal-title":"Lancet"},{"issue":"4","key":"3667_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1432-2277.2005.00080.x","volume":"18","author":"AG Jardine","year":"2005","unstructured":"Jardine AG. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int. 2005;18(4):379\u201384.","journal-title":"Transpl Int"},{"issue":"4","key":"3667_CR36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/00005344-200210000-00017","volume":"40","author":"LA Cal\u00f2","year":"2002","unstructured":"Cal\u00f2 LA, Davis PA, Giacon B, et al. Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002;40(4):625\u201331.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"3667_CR37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","volume":"4","author":"O Heisel","year":"2004","unstructured":"Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transpl. 2004;4(4):583\u201395.","journal-title":"Am J Transpl"},{"issue":"8","key":"3667_CR38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/hrt.2003.031492","volume":"90","author":"MK Ng","year":"2004","unstructured":"Ng MK, Celermajer DS. Glucocorticoid treatment and cardiovascular disease. Heart. 2004;90(8):829\u201330.","journal-title":"Heart"},{"issue":"5","key":"3667_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1530\/EJE-07-0455","volume":"157","author":"BR Walker","year":"2007","unstructured":"Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157(5):545\u201359.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"3667_CR40","doi-asserted-by":"publisher","first-page":"250","DOI":"10.23876\/j.krcp.20.174","volume":"40","author":"CC Lim","year":"2021","unstructured":"Lim CC, Choo JCJ, Tan HZ, et al. Changes in metabolic parameters and adverse kidney and cardiovascular events during glomerulonephritis and renal vasculitis treatment in patients with and without diabetes mellitus. Kidney Res Clin Pract. 2021;40(2):250\u201362.","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"3667_CR41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12882-017-0511-z","volume":"18","author":"HL Hutton","year":"2017","unstructured":"Hutton HL, Levin A, Gill J, Djurdjev O, Tang M, Barbour SJ. Cardiovascular risk is similar in patients with glomerulonephritis compared to other types of chronic kidney disease: a matched cohort study. BMC Nephrol. 2017;18(1):95.","journal-title":"BMC Nephrol"},{"issue":"662","key":"3667_CR42","doi-asserted-by":"publisher","first-page":"e643","DOI":"10.3399\/bjgp17X692153","volume":"67","author":"BL Stuart","year":"2017","unstructured":"Stuart BL, Grebel LE, Butler CC, Hood K, Verheij TJM, Little P. Comparison between treatment effects in a randomised controlled trial and an observational study using propensity scores in primary care. Br J Gen Pract. 2017;67(662):e643\u20139.","journal-title":"Br J Gen Pract"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03667-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03667-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03667-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T08:03:01Z","timestamp":1721635381000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03667-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3667"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03667-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"<i>As a federated research network<\/i>,<i> studies using TriNetX do not require research ethical approval as no patient\u2019s identifiable information is received.<\/i>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"<i>Not applicable<\/i>.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"233"}}